ID   TF2B_HUMAN              Reviewed;         316 AA.
AC   Q00403; A8K1A7; Q5JS30;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   07-APR-2021, entry version 221.
DE   RecName: Full=Transcription initiation factor IIB {ECO:0000303|PubMed:1876184};
DE            EC=2.3.1.48 {ECO:0000269|PubMed:12931194};
DE   AltName: Full=General transcription factor TFIIB {ECO:0000303|PubMed:1946368};
DE   AltName: Full=S300-II {ECO:0000303|PubMed:1517211};
GN   Name=GTF2B; Synonyms=TF2B, TFIIB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND ASSOCIATION WITH THE TFIID-TFIIA
RP   COMPLEX.
RX   PubMed=1876184; DOI=10.1038/352689a0;
RA   Ha I., Lane W.S., Reinberg D.;
RT   "Cloning of a human gene encoding the general transcription initiation
RT   factor IIB.";
RL   Nature 352:689-695(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=1946368; DOI=10.1073/pnas.88.21.9553;
RA   Malik S., Hisatake K., Sumimoto H., Horikoshi M., Roeder R.G.;
RT   "Sequence of general transcription factor TFIIB and relationships to other
RT   initiation factors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9553-9557(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 6-316, FUNCTION, AND INTERACTION WITH ESR1;
RP   NR2F1 AND PGR.
RX   PubMed=1517211;
RA   Ing N.H., Beekman J.M., Tsai S.Y., Tsai M.J., O'Malley B.W.;
RT   "Members of the steroid hormone receptor superfamily interact with TFIIB
RT   (S300-II).";
RL   J. Biol. Chem. 267:17617-17623(1992).
RN   [8]
RP   FUNCTION, AND IDENTIFICATION IN A RNA POLYMERASE II INITIATION COMPLEX.
RX   PubMed=3818643;
RA   Reinberg D., Horikoshi M., Roeder R.G.;
RT   "Factors involved in specific transcription in mammalian RNA polymerase II.
RT   Functional analysis of initiation factors IIA and IID and identification of
RT   a new factor operating at sequences downstream of the initiation site.";
RL   J. Biol. Chem. 262:3322-3330(1987).
RN   [9]
RP   FUNCTION, AND IDENTIFICATION IN A RNA POLYMERASE II INITIATION COMPLEX.
RX   PubMed=3029109;
RA   Reinberg D., Roeder R.G.;
RT   "Factors involved in specific transcription by mammalian RNA polymerase II.
RT   Purification and functional analysis of initiation factors IIB and IIE.";
RL   J. Biol. Chem. 262:3310-3321(1987).
RN   [10]
RP   ASSOCIATION WITH THE TFIID-TFIIA COMPLEX.
RX   PubMed=2247058; DOI=10.1128/mcb.10.12.6335;
RA   Maldonado E., Ha I., Cortes P., Weis L., Reinberg D.;
RT   "Factors involved in specific transcription by mammalian RNA polymerase II:
RT   role of transcription factors IIA, IID, and IIB during formation of a
RT   transcription-competent complex.";
RL   Mol. Cell. Biol. 10:6335-6347(1990).
RN   [11]
RP   FUNCTION, INTERACTION WITH GTF2F2; RNA POLYMERASE II AND TBP, AND
RP   MUTAGENESIS OF ARG-286; ARG-290 AND ARG-295.
RX   PubMed=8504927; DOI=10.1101/gad.7.6.1021;
RA   Ha I., Roberts S., Maldonado E., Sun X., Kim L.U., Green M., Reinberg D.;
RT   "Multiple functional domains of human transcription factor IIB: distinct
RT   interactions with two general transcription factors and RNA polymerase
RT   II.";
RL   Genes Dev. 7:1021-1032(1993).
RN   [12]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 ICP4 (MICROBIAL INFECTION).
RX   PubMed=8392607; DOI=10.1128/jvi.67.8.4676-4687.1993;
RA   Smith C.A., Bates P., Rivera-Gonzalez R., Gu B., DeLuca N.A.;
RT   "ICP4, the major transcriptional regulatory protein of herpes simplex virus
RT   type 1, forms a tripartite complex with TATA-binding protein and TFIIB.";
RL   J. Virol. 67:4676-4687(1993).
RN   [13]
RP   FUNCTION, IDENTIFICATION IN A RNA POLYMERASE II INITIATION COMPLEX,
RP   INTERACTION WITH RNA POLYMERASE II, AND DOMAIN.
RX   PubMed=8413225; DOI=10.1128/mcb.13.10.6253;
RA   Malik S., Lee D.K., Roeder R.G.;
RT   "Potential RNA polymerase II-induced interactions of transcription factor
RT   TFIIB.";
RL   Mol. Cell. Biol. 13:6253-6259(1993).
RN   [14]
RP   INTERACTION WITH HERPES VIRUS ACTIVATOR PROTEIN VP16 (MICROBIAL INFECTION),
RP   AND MUTAGENESIS OF ARG-185; LYS-189; ARG-193; LYS-196 AND LYS-200.
RX   PubMed=8515819; DOI=10.1038/363741a0;
RA   Roberts S.G., Ha I., Maldonado E., Reinberg D., Green M.R.;
RT   "Interaction between an acidic activator and transcription factor TFIIB is
RT   required for transcriptional activation.";
RL   Nature 363:741-744(1993).
RN   [15]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH TATA BOX-BOUND TBP, AND DOMAINS.
RX   PubMed=8515820; DOI=10.1038/363744a08316289;
RA   Hisatake K., Roeder R.G., Horikoshi M.;
RT   "Functional dissection of TFIIB domains required for TFIIB-TFIID-promoter
RT   complex formation and basal transcription activity.";
RL   Nature 363:744-747(1993).
RN   [16]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH TATA BOX-BOUND TBP, AND DOMAINS.
RX   PubMed=8516311; DOI=10.1073/pnas.90.12.5628;
RA   Barberis A., Mueller C.W., Harrison S.C., Ptashne M.;
RT   "Delineation of two functional regions of transcription factor TFIIB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5628-5632(1993).
RN   [17]
RP   FUNCTION, IDENTIFICATION IN A RNA POLYMERASE II INITIATION COMPLEX, DOMAIN,
RP   AND MUTAGENESIS OF CYS-37 AND GLY-247.
RX   PubMed=8516312; DOI=10.1073/pnas.90.12.5633;
RA   Buratowski S., Zhou H.;
RT   "Functional domains of transcription factor TFIIB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5633-5637(1993).
RN   [18]
RP   INTERACTION WITH TCEA2.
RX   PubMed=8566795; DOI=10.1016/0378-1119(95)00634-6;
RA   Umehara T., Kida S., Yamamoto T., Horikoshi M.;
RT   "Isolation and characterization of a cDNA encoding a new type of human
RT   transcription elongation factor S-II.";
RL   Gene 167:297-302(1995).
RN   [19]
RP   FUNCTION, AND IDENTIFICATION IN A RNA POLYMERASE II INITIATION COMPLEX.
RX   PubMed=7601352; DOI=10.1101/gad.9.12.1479;
RA   Zawel L., Kumar K.P., Reinberg D.;
RT   "Recycling of the general transcription factors during RNA polymerase II
RT   transcription.";
RL   Genes Dev. 9:1479-1490(1995).
RN   [20]
RP   INTERACTION WITH EBV EBNA2 (MICROBIAL INFECTION).
RX   PubMed=7983760; DOI=10.1128/jvi.69.1.585-588.1995;
RA   Tong X., Wang F., Thut C.J., Kieff E.;
RT   "The Epstein-Barr virus nuclear protein 2 acidic domain can interact with
RT   TFIIB, TAF40, and RPA70 but not with TATA-binding protein.";
RL   J. Virol. 69:585-588(1995).
RN   [21]
RP   INTERACTION WITH GTF2F1 AND GTF2F2, AND REGION.
RX   PubMed=8662660; DOI=10.1074/jbc.271.20.11703;
RA   Fang S.M., Burton Z.F.;
RT   "RNA polymerase II-associated protein (RAP) 74 binds transcription factor
RT   (TF) IIB and blocks TFIIB-RAP30 binding.";
RL   J. Biol. Chem. 271:11703-11709(1996).
RN   [22]
RP   INTERACTION WITH HIV-1 VPR (MICROBIAL INFECTION).
RX   PubMed=8800208; DOI=10.1006/jmbi.1996.0485;
RA   Agostini I., Navarro J.-M., Rey F., Bouhamdan M., Spire B., Vigne R.,
RA   Sire J.;
RT   "The human immunodeficiency virus type 1 Vpr transactivator: cooperation
RT   with promoter-bound activator domains and binding to TFIIB.";
RL   J. Mol. Biol. 261:599-606(1996).
RN   [23]
RP   FUNCTION, DNA-BINDING, AND MUTAGENESIS OF VAL-283 AND ARG-286.
RX   PubMed=9420329; DOI=10.1101/gad.12.1.34;
RA   Lagrange T., Kapanidis A.N., Tang H., Reinberg D., Ebright R.H.;
RT   "New core promoter element in RNA polymerase II-dependent transcription:
RT   sequence-specific DNA binding by transcription factor IIB.";
RL   Genes Dev. 12:34-44(1998).
RN   [24]
RP   MUTAGENESIS OF 52-GLU--SER-56.
RX   PubMed=10359081; DOI=10.1016/s0014-5793(99)00501-3;
RA   Agostini I., Navarro J.M., Bouhamdan M., Willetts K., Rey F., Spire B.,
RA   Vigne R., Pomerantz R., Sire J.;
RT   "The HIV-1 Vpr co-activator induces a conformational change in TFIIB.";
RL   FEBS Lett. 450:235-239(1999).
RN   [25]
RP   FUNCTION, AND MUTAGENESIS OF GLU-51 AND ARG-66.
RX   PubMed=10318856; DOI=10.1074/jbc.274.20.14337;
RA   Hawkes N.A., Roberts S.G.;
RT   "The role of human TFIIB in transcription start site selection in vitro and
RT   in vivo.";
RL   J. Biol. Chem. 274:14337-14343(1999).
RN   [26]
RP   INTERACTION WITH HSF1.
RX   PubMed=11005381; DOI=10.1379/1466-1268(2000)005<0229:ptfhwt>2.0.co;2;
RA   Yuan C.X., Gurley W.B.;
RT   "Potential targets for HSF1 within the preinitiation complex.";
RL   Cell Stress Chaperones 5:229-242(2000).
RN   [27]
RP   FUNCTION, ACETYLATION AT LYS-238, AUTOACETYLATION, CATALYTIC ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION WITH GTF2F1, SUBCELLULAR
RP   LOCATION, MUTAGENESIS OF LYS-238, CHROMATIN-BINDING, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=12931194; DOI=10.1038/nature01899;
RA   Choi C.H., Hiromura M., Usheva A.;
RT   "Transcription factor IIB acetylates itself to regulate transcription.";
RL   Nature 424:965-969(2003).
RN   [28]
RP   FUNCTION, AND MUTAGENESIS OF GLY-153.
RX   PubMed=16230532; DOI=10.1101/gad.342405;
RA   Deng W., Roberts S.G.;
RT   "A core promoter element downstream of the TATA box that is recognized by
RT   TFIIB.";
RL   Genes Dev. 19:2418-2423(2005).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; SER-76 AND SER-92, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   FUNCTION, FUNCTION IN HSV-1 TRANSCRIPTION AND REPLICATION (MICROBIAL
RP   INFECTION), SUBCELLULAR LOCATION, CHROMATIN-BINDING, ACETYLATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=24441171; DOI=10.1038/srep03664;
RA   Gelev V., Zabolotny J.M., Lange M., Hiromura M., Yoo S.W., Orlando J.S.,
RA   Kushnir A., Horikoshi N., Paquet E., Bachvarov D., Schaffer P.A.,
RA   Usheva A.;
RT   "A new paradigm for transcription factor TFIIB functionality.";
RL   Sci. Rep. 4:3664-3664(2014).
RN   [34]
RP   STRUCTURE BY NMR OF 111-316.
RX   PubMed=7671313; DOI=10.1016/0092-8674(95)90483-2;
RA   Bagby S., Kim S., Maldonado E., Tong K.I., Reinberg D., Ikura M.;
RT   "Solution structure of the C-terminal core domain of human TFIIB:
RT   similarity to cyclin A and interaction with TATA-binding protein.";
RL   Cell 82:857-867(1995).
RN   [35] {ECO:0007744|PDB:1VOL}
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 113-316 IN COMPLEX WITH PLANT TATA
RP   BOX-BINDING PROTEIN AND DNA, AND DNA-BINDING.
RX   PubMed=7675079; DOI=10.1038/377119a0;
RA   Nikolov D.B., Chen H., Halay E.D., Usheva A.A., Hisatake K., Lee D.K.,
RA   Roeder R.G., Burley S.K.;
RT   "Crystal structure of a TFIIB-TBP-TATA-element ternary complex.";
RL   Nature 377:119-128(1995).
RN   [36] {ECO:0007744|PDB:1TFB}
RP   STRUCTURE BY NMR OF 112-316.
RX   PubMed=9609687; DOI=10.1021/bi9801098;
RA   Hayashi F., Ishima R., Liu D., Tong K.I., Kim S., Reinberg D., Bagby S.,
RA   Ikura M.;
RT   "Human general transcription factor TFIIB: conformational variability and
RT   interaction with VP16 activation domain.";
RL   Biochemistry 37:7941-7951(1998).
RN   [37] {ECO:0007744|PDB:1C9B}
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 110-316 IN COMPLEX WITH TBP AND
RP   DNA, INTERACTION WITH TBP, AND DNA-BINDING.
RX   PubMed=10619841; DOI=10.1093/emboj/19.1.25;
RA   Tsai F.T.F., Sigler P.B.;
RT   "Structural basis of preinitiation complex assembly on human pol II
RT   promoters.";
RL   EMBO J. 19:25-36(2000).
RN   [38] {ECO:0007744|PDB:1DL6}
RP   STRUCTURE BY NMR OF 2-59 IN COMPLEX WITH ZINC.
RX   PubMed=11045620; DOI=10.1110/ps.9.9.1743;
RA   Chen H.T., Legault P., Glushka J., Omichinski J.G., Scott R.A.;
RT   "Structure of a (Cys3His) zinc ribbon, a ubiquitous motif in archaeal and
RT   eucaryal transcription.";
RL   Protein Sci. 9:1743-1752(2000).
RN   [39] {ECO:0007744|PDB:1RLY, ECO:0007744|PDB:1RO4}
RP   STRUCTURE BY NMR OF 1-60 IN APO AND -BOUND FORMS IN COMPLEX WITH ZINC.
RX   PubMed=14641108; DOI=10.1042/bj20031706;
RA   Ghosh M., Elsby L.M., Mal T.K., Gooding J.M., Roberts S.G., Ikura M.;
RT   "Probing Zn2+-binding effects on the zinc-ribbon domain of human general
RT   transcription factor TFIIB.";
RL   Biochem. J. 378:317-324(2004).
RN   [40] {ECO:0007744|PDB:2PHG}
RP   STRUCTURE BY NMR OF 111-316 IN COMPLEX WITH HERPES VIRUS ACTIVATOR PROTEIN
RP   VP16, AND INTERACTION WITH VP16 (MICROBIAL INFECTION).
RX   PubMed=15654739; DOI=10.1021/bi0482912;
RA   Jonker H.R., Wechselberger R.W., Boelens R., Folkers G.E., Kaptein R.;
RT   "Structural properties of the promiscuous VP16 activation domain.";
RL   Biochemistry 44:827-839(2005).
RN   [41] {ECO:0007744|PDB:5IY6, ECO:0007744|PDB:5IY7, ECO:0007744|PDB:5IY8, ECO:0007744|PDB:5IY9, ECO:0007744|PDB:5IYA, ECO:0007744|PDB:5IYB, ECO:0007744|PDB:5IYC, ECO:0007744|PDB:5IYD}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.90 ANGSTROMS), FUNCTION, AND SUBUNIT.
RX   PubMed=27193682; DOI=10.1038/nature17970;
RA   He Y., Yan C., Fang J., Inouye C., Tjian R., Ivanov I., Nogales E.;
RT   "Near-atomic resolution visualization of human transcription promoter
RT   opening.";
RL   Nature 533:359-365(2016).
RN   [42] {ECO:0007744|PDB:5WH1}
RP   X-RAY CRYSTALLOGRAPHY (3.39 ANGSTROMS) OF 107-316 OF APOPROTEIN,
RP   IDENTIFICATION IN A COMPLEX WITH TATA BOX-BOUND TBP, INTERACTION WITH
RP   SSU72, AND MUTAGENESIS OF ARG-185; LYS-189; ARG-193; 200-LYS--LEU-208;
RP   LYS-200 AND LEU-208.
RX   PubMed=29158257; DOI=10.1074/jbc.m117.811521;
RA   Bratkowski M., Unarta I.C., Zhu L., Shubbar M., Huang X., Liu X.;
RT   "Structural dissection of an interaction between transcription initiation
RT   and termination factors implicated in promoter-terminator cross-talk.";
RL   J. Biol. Chem. 293:1651-1665(2018).
RN   [43]
RP   VARIANT [LARGE SCALE ANALYSIS] GLN-132.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: General transcription factor that plays a role in
CC       transcription initiation by RNA polymerase II (Pol II). Involved in the
CC       pre-initiation complex (PIC) formation and Pol II recruitment at
CC       promoter DNA (PubMed:1876184, PubMed:1946368, PubMed:1517211,
CC       PubMed:3818643, PubMed:3029109, PubMed:8413225, PubMed:8515820,
CC       PubMed:8516311, PubMed:8516312, PubMed:7601352, PubMed:9420329,
CC       PubMed:12931194, PubMed:27193682). Together with the TATA box-bound TBP
CC       forms the core initiation complex and provides a bridge between TBP and
CC       the Pol II-TFIIF complex (PubMed:8504927, PubMed:8413225,
CC       PubMed:8515820, PubMed:8516311, PubMed:8516312). Released from the PIC
CC       early following the onset of transcription during the initiation and
CC       elongation transition and reassociates with TBP during the next
CC       transcription cycle (PubMed:7601352). Associates with chromatin to core
CC       promoter-specific regions (PubMed:12931194, PubMed:24441171). Binds to
CC       two distinct DNA core promoter consensus sequence elements in a TBP-
CC       independent manner; these IIB-recognition elements (BREs) are localized
CC       immediately upstream (BREu), 5'-[GC][GC][GA]CGCC-3', and downstream
CC       (BREd), 5'-[GA]T[TGA][TG][GT][TG][TG]-3', of the TATA box element
CC       (PubMed:9420329, PubMed:16230532, PubMed:7675079, PubMed:10619841).
CC       Modulates transcription start site selection (PubMed:10318856).
CC       Exhibits also autoacetyltransferase activity that contributes to the
CC       activated transcription (PubMed:12931194).
CC       {ECO:0000269|PubMed:10318856, ECO:0000269|PubMed:10619841,
CC       ECO:0000269|PubMed:12931194, ECO:0000269|PubMed:1517211,
CC       ECO:0000269|PubMed:16230532, ECO:0000269|PubMed:1876184,
CC       ECO:0000269|PubMed:1946368, ECO:0000269|PubMed:24441171,
CC       ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:3029109,
CC       ECO:0000269|PubMed:3818643, ECO:0000269|PubMed:7601352,
CC       ECO:0000269|PubMed:7675079, ECO:0000269|PubMed:8413225,
CC       ECO:0000269|PubMed:8504927, ECO:0000269|PubMed:8515820,
CC       ECO:0000269|PubMed:8516311, ECO:0000269|PubMed:8516312,
CC       ECO:0000269|PubMed:9420329}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=acetyl-CoA + L-lysyl-[protein] = CoA + H(+) + N(6)-acetyl-L-
CC         lysyl-[protein]; Xref=Rhea:RHEA:45948, Rhea:RHEA-COMP:9752,
CC         Rhea:RHEA-COMP:10731, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57288, ChEBI:CHEBI:61930; EC=2.3.1.48;
CC         Evidence={ECO:0000269|PubMed:12931194};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.117 mM for acetyl-CoA {ECO:0000269|PubMed:12931194};
CC   -!- SUBUNIT: Found in a ternary complex with TATA box-bound TBP
CC       (PubMed:8413225, PubMed:8515820, PubMed:8516311, PubMed:8516312,
CC       PubMed:10619841, PubMed:29158257). Part of a TFIID-containing RNA
CC       polymerase II pre-initiation complex (PIC) that is composed of TBP and
CC       at least GTF2A1, GTF2A2, GTF2E1, GTF2E2, GTF2F1, GTF2H2, GTF2H3,
CC       GTF2H4, GTF2H5, GTF2B, TCEA1, ERCC2, ERCC3, TAF1, TAF2, TAF3, TAF4,
CC       TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13
CC       (PubMed:27193682). Associates with TFIID-TFIIA (DA complex) to form
CC       TFIID-TFIIA-TFIIB (DAB complex), which is then recognized by RNA
CC       polymerase II (Pol II) (PubMed:1876184, PubMed:2247058). Found in a RNA
CC       polymerase II initiation complex (PubMed:3818643, PubMed:3029109,
CC       PubMed:8413225, PubMed:8516312, PubMed:7601352). Interacts (via C-
CC       terminus) with TBP; this interaction with TATA box-bound TBP guides Pol
CC       II into the PIC (PubMed:8504927, PubMed:10619841). Interacts (via N-
CC       terminus) with Pol II (PubMed:8504927, PubMed:8413225). Interacts (via
CC       C-terminus) with SSU72; this interaction is inhibited by SYMPK
CC       (PubMed:29158257). Interacts with NR2F1; this interaction is direct
CC       (PubMed:1517211). Interacts with PGR (PubMed:1517211). Interacts with
CC       ESR1 (PubMed:1517211). Interacts with GTF2F1 (via C-terminus and
CC       preferentially via acetylated form); this interaction prevents binding
CC       of GTF2B to GTF2F2 (PubMed:8662660, PubMed:12931194). Interacts with
CC       GTF2F2 (via N-terminus); this interaction is inhibited in presence of
CC       GTF2F1 (PubMed:8504927, PubMed:8662660). Interacts with the
CC       transcription elongation factor TCEA2 (PubMed:8566795). Interacts with
CC       HSF1 (via transactivation domain) (PubMed:11005381). Interacts with
CC       GPBP1 (By similarity). {ECO:0000250|UniProtKB:P62915,
CC       ECO:0000269|PubMed:10619841, ECO:0000269|PubMed:11005381,
CC       ECO:0000269|PubMed:12931194, ECO:0000269|PubMed:1517211,
CC       ECO:0000269|PubMed:1876184, ECO:0000269|PubMed:2247058,
CC       ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:29158257,
CC       ECO:0000269|PubMed:3029109, ECO:0000269|PubMed:3818643,
CC       ECO:0000269|PubMed:7601352, ECO:0000269|PubMed:8413225,
CC       ECO:0000269|PubMed:8504927, ECO:0000269|PubMed:8515820,
CC       ECO:0000269|PubMed:8516311, ECO:0000269|PubMed:8516312,
CC       ECO:0000269|PubMed:8566795, ECO:0000269|PubMed:8662660}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Vpr.
CC       {ECO:0000269|PubMed:8800208}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus EBNA2.
CC       {ECO:0000269|PubMed:7983760}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Herpes simplex virus 1
CC       protein ICP4. {ECO:0000269|PubMed:8392607}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via C-terminus) with the
CC       Herpes simplex virus activator VP16; this interaction stimulates RNA
CC       Pol II transcription by increasing the extent of pre-initiation complex
CC       assembly. {ECO:0000269|PubMed:15654739, ECO:0000269|PubMed:8515819}.
CC   -!- INTERACTION:
CC       Q00403; P13928: ANXA8; NbExp=3; IntAct=EBI-389564, EBI-2556915;
CC       Q00403; P05067: APP; NbExp=3; IntAct=EBI-389564, EBI-77613;
CC       Q00403; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-389564, EBI-10254793;
CC       Q00403; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-389564, EBI-742750;
CC       Q00403; Q9H972-2: C14orf93; NbExp=3; IntAct=EBI-389564, EBI-11524174;
CC       Q00403; Q13191: CBLB; NbExp=3; IntAct=EBI-389564, EBI-744027;
CC       Q00403; Q14781-2: CBX2; NbExp=3; IntAct=EBI-389564, EBI-11974585;
CC       Q00403; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-389564, EBI-9087876;
CC       Q00403; Q5TAQ9-2: DCAF8; NbExp=3; IntAct=EBI-389564, EBI-25842815;
CC       Q00403; Q14919: DRAP1; NbExp=6; IntAct=EBI-389564, EBI-712941;
CC       Q00403; Q09472: EP300; NbExp=2; IntAct=EBI-389564, EBI-447295;
CC       Q00403; Q17RN3: FAM98C; NbExp=3; IntAct=EBI-389564, EBI-5461838;
CC       Q00403; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-389564, EBI-8468186;
CC       Q00403; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-389564, EBI-5916454;
CC       Q00403; Q9HCC6: HES4; NbExp=3; IntAct=EBI-389564, EBI-2680288;
CC       Q00403; Q13123: IK; NbExp=3; IntAct=EBI-389564, EBI-713456;
CC       Q00403; Q92613: JADE3; NbExp=3; IntAct=EBI-389564, EBI-10278909;
CC       Q00403; Q9UIH9: KLF15; NbExp=3; IntAct=EBI-389564, EBI-2796400;
CC       Q00403; Q14693: LPIN1; NbExp=3; IntAct=EBI-389564, EBI-5278370;
CC       Q00403; Q15049: MLC1; NbExp=3; IntAct=EBI-389564, EBI-8475277;
CC       Q00403; P01106: MYC; NbExp=3; IntAct=EBI-389564, EBI-447544;
CC       Q00403; O15381-5: NVL; NbExp=3; IntAct=EBI-389564, EBI-18577082;
CC       Q00403; Q9BYU1: PBX4; NbExp=3; IntAct=EBI-389564, EBI-10302990;
CC       Q00403; Q5T6S3: PHF19; NbExp=3; IntAct=EBI-389564, EBI-2339674;
CC       Q00403; P19388: POLR2E; NbExp=5; IntAct=EBI-389564, EBI-395189;
CC       Q00403; Q96D59: RNF183; NbExp=3; IntAct=EBI-389564, EBI-743938;
CC       Q00403; Q9BUL9: RPP25; NbExp=3; IntAct=EBI-389564, EBI-366570;
CC       Q00403; P62701: RPS4X; NbExp=3; IntAct=EBI-389564, EBI-354303;
CC       Q00403; Q9BVN2: RUSC1; NbExp=3; IntAct=EBI-389564, EBI-6257312;
CC       Q00403; Q8N488: RYBP; NbExp=3; IntAct=EBI-389564, EBI-752324;
CC       Q00403; O75446: SAP30; NbExp=3; IntAct=EBI-389564, EBI-632609;
CC       Q00403; P60896: SEM1; NbExp=3; IntAct=EBI-389564, EBI-79819;
CC       Q00403; Q8NHS9: SPATA22; NbExp=3; IntAct=EBI-389564, EBI-7067260;
CC       Q00403; Q8TCT7-2: SPPL2B; NbExp=3; IntAct=EBI-389564, EBI-8345366;
CC       Q00403; O60506-4: SYNCRIP; NbExp=3; IntAct=EBI-389564, EBI-11123832;
CC       Q00403; P20226: TBP; NbExp=2; IntAct=EBI-389564, EBI-355371;
CC       Q00403; O43615: TIMM44; NbExp=3; IntAct=EBI-389564, EBI-861737;
CC       Q00403; Q15025: TNIP1; NbExp=7; IntAct=EBI-389564, EBI-357849;
CC       Q00403; Q7Z2T5: TRMT1L; NbExp=3; IntAct=EBI-389564, EBI-1237316;
CC       Q00403; O75604-3: USP2; NbExp=3; IntAct=EBI-389564, EBI-10696113;
CC       Q00403; P58304: VSX2; NbExp=3; IntAct=EBI-389564, EBI-6427899;
CC       Q00403; Q96MN9-2: ZNF488; NbExp=3; IntAct=EBI-389564, EBI-25831733;
CC       Q00403; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-389564, EBI-18036029;
CC       Q00403; Q8NBB4-2: ZSCAN1; NbExp=3; IntAct=EBI-389564, EBI-12021938;
CC       Q00403; P10073: ZSCAN22; NbExp=3; IntAct=EBI-389564, EBI-10178224;
CC       Q00403; P46077: GRF4; Xeno; NbExp=2; IntAct=EBI-389564, EBI-637479;
CC       Q00403; P87662: ICP0; Xeno; NbExp=3; IntAct=EBI-389564, EBI-11712595;
CC       Q00403; P17473: IE; Xeno; NbExp=4; IntAct=EBI-389564, EBI-11702772;
CC       Q00403; P48281: Vdr; Xeno; NbExp=2; IntAct=EBI-389564, EBI-346797;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12931194}. Chromosome
CC       {ECO:0000269|PubMed:24441171}. Note=Non-acetylated form colocalizes
CC       with DNA in the G0/1, S and G2 phases of the cell cycle, but not during
CC       mitosis (PubMed:24441171). Acetylated form colocalizes at
CC       transcriptionally silent mitotic chromatids during mitosis at
CC       metaphase, anaphase, and telophase phases of the cell cycle
CC       (PubMed:24441171). {ECO:0000269|PubMed:24441171}.
CC   -!- TISSUE SPECIFICITY: Expressed in the inner cell mass forming the
CC       embryoblast (PubMed:24441171). Not detected in cells from the outer
CC       thin layer trophoblast (at protein level) (PubMed:24441171).
CC       {ECO:0000269|PubMed:24441171}.
CC   -!- DOMAIN: The TFIIB-type zinc-binding domain is necessary for the
CC       interaction and recruitment of RNA polymerase II to the core promoter,
CC       the formation of a fully competent pre-initiation complex (PIC)
CC       assembly and basal transcription initiation (PubMed:8515820,
CC       PubMed:8516311, PubMed:8516312, PubMed:8413225). The C-terminus is
CC       necessary and sufficient for interaction with the TATA box-bound TBP
CC       complex and for the formation of PIC (PubMed:8515820, PubMed:8516311,
CC       PubMed:8413225). {ECO:0000269|PubMed:8413225,
CC       ECO:0000269|PubMed:8515820, ECO:0000269|PubMed:8516311,
CC       ECO:0000269|PubMed:8516312}.
CC   -!- PTM: Acetylated (PubMed:24441171). Autoacetylated; autoacetylation at
CC       Lys-238 stimulates transcription activation (PubMed:12931194).
CC       {ECO:0000269|PubMed:12931194, ECO:0000269|PubMed:24441171}.
CC   -!- SIMILARITY: Belongs to the TFIIB family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X59268; CAA41958.1; -; mRNA.
DR   EMBL; M76766; AAA61149.1; -; mRNA.
DR   EMBL; AK289822; BAF82511.1; -; mRNA.
DR   EMBL; AB451296; BAG70110.1; -; mRNA.
DR   EMBL; AL445991; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC020597; AAH20597.1; -; mRNA.
DR   EMBL; S44184; AAB23144.1; -; mRNA.
DR   CCDS; CCDS715.1; -.
DR   PIR; S17654; TWHU2B.
DR   RefSeq; NP_001505.1; NM_001514.5.
DR   PDB; 1C9B; X-ray; 2.65 A; A/E/I/M/Q=110-316.
DR   PDB; 1DL6; NMR; -; A=2-59.
DR   PDB; 1RLY; NMR; -; A=1-60.
DR   PDB; 1RO4; NMR; -; A=1-60.
DR   PDB; 1TFB; NMR; -; A=112-316.
DR   PDB; 1VOL; X-ray; 2.70 A; A=113-316.
DR   PDB; 2PHG; NMR; -; A=112-316.
DR   PDB; 5IY6; EM; 7.20 A; M=1-316.
DR   PDB; 5IY7; EM; 8.60 A; M=1-316.
DR   PDB; 5IY8; EM; 7.90 A; M=1-316.
DR   PDB; 5IY9; EM; 6.30 A; M=1-316.
DR   PDB; 5IYA; EM; 5.40 A; M=1-316.
DR   PDB; 5IYB; EM; 3.90 A; M=1-316.
DR   PDB; 5IYC; EM; 3.90 A; M=1-316.
DR   PDB; 5IYD; EM; 3.90 A; M=1-316.
DR   PDB; 5WH1; X-ray; 3.39 A; A/B/C/D=107-316.
DR   PDB; 6O9L; EM; 7.20 A; M=1-316.
DR   PDBsum; 1C9B; -.
DR   PDBsum; 1DL6; -.
DR   PDBsum; 1RLY; -.
DR   PDBsum; 1RO4; -.
DR   PDBsum; 1TFB; -.
DR   PDBsum; 1VOL; -.
DR   PDBsum; 2PHG; -.
DR   PDBsum; 5IY6; -.
DR   PDBsum; 5IY7; -.
DR   PDBsum; 5IY8; -.
DR   PDBsum; 5IY9; -.
DR   PDBsum; 5IYA; -.
DR   PDBsum; 5IYB; -.
DR   PDBsum; 5IYC; -.
DR   PDBsum; 5IYD; -.
DR   PDBsum; 5WH1; -.
DR   PDBsum; 6O9L; -.
DR   SMR; Q00403; -.
DR   BioGRID; 109214; 99.
DR   CORUM; Q00403; -.
DR   DIP; DIP-1077N; -.
DR   IntAct; Q00403; 94.
DR   MINT; Q00403; -.
DR   STRING; 9606.ENSP00000359531; -.
DR   iPTMnet; Q00403; -.
DR   MetOSite; Q00403; -.
DR   PhosphoSitePlus; Q00403; -.
DR   BioMuta; GTF2B; -.
DR   DMDM; 135629; -.
DR   EPD; Q00403; -.
DR   jPOST; Q00403; -.
DR   MassIVE; Q00403; -.
DR   MaxQB; Q00403; -.
DR   PaxDb; Q00403; -.
DR   PeptideAtlas; Q00403; -.
DR   PRIDE; Q00403; -.
DR   ProteomicsDB; 57846; -.
DR   Antibodypedia; 19819; 421 antibodies.
DR   DNASU; 2959; -.
DR   Ensembl; ENST00000370500; ENSP00000359531; ENSG00000137947.
DR   GeneID; 2959; -.
DR   KEGG; hsa:2959; -.
DR   UCSC; uc001dmo.5; human.
DR   CTD; 2959; -.
DR   DisGeNET; 2959; -.
DR   GeneCards; GTF2B; -.
DR   HGNC; HGNC:4648; GTF2B.
DR   HPA; ENSG00000137947; Low tissue specificity.
DR   MIM; 189963; gene.
DR   neXtProt; NX_Q00403; -.
DR   OpenTargets; ENSG00000137947; -.
DR   PharmGKB; PA29035; -.
DR   VEuPathDB; HostDB:ENSG00000137947.11; -.
DR   eggNOG; KOG1597; Eukaryota.
DR   GeneTree; ENSGT00390000006671; -.
DR   InParanoid; Q00403; -.
DR   OMA; DQRMKRS; -.
DR   OrthoDB; 729732at2759; -.
DR   PhylomeDB; Q00403; -.
DR   TreeFam; TF105953; -.
DR   PathwayCommons; Q00403; -.
DR   Reactome; R-HSA-167161; HIV Transcription Initiation.
DR   Reactome; R-HSA-167162; RNA Polymerase II HIV Promoter Escape.
DR   Reactome; R-HSA-167172; Transcription of the HIV genome.
DR   Reactome; R-HSA-674695; RNA Polymerase II Pre-transcription Events.
DR   Reactome; R-HSA-6807505; RNA polymerase II transcribes snRNA genes.
DR   Reactome; R-HSA-73776; RNA Polymerase II Promoter Escape.
DR   Reactome; R-HSA-73779; RNA Polymerase II Transcription Pre-Initiation And Promoter Opening.
DR   Reactome; R-HSA-75953; RNA Polymerase II Transcription Initiation.
DR   Reactome; R-HSA-76042; RNA Polymerase II Transcription Initiation And Promoter Clearance.
DR   SIGNOR; Q00403; -.
DR   BioGRID-ORCS; 2959; 800 hits in 1008 CRISPR screens.
DR   ChiTaRS; GTF2B; human.
DR   EvolutionaryTrace; Q00403; -.
DR   GeneWiki; Transcription_factor_II_B; -.
DR   GenomeRNAi; 2959; -.
DR   Pharos; Q00403; Tbio.
DR   PRO; PR:Q00403; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q00403; protein.
DR   Bgee; ENSG00000137947; Expressed in oocyte and 237 other tissues.
DR   ExpressionAtlas; Q00403; baseline and differential.
DR   Genevisible; Q00403; HS.
DR   GO; GO:0005694; C:chromosome; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:UniProtKB.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IDA:UniProtKB.
DR   GO; GO:0005669; C:transcription factor TFIID complex; IDA:UniProtKB.
DR   GO; GO:0097550; C:transcription preinitiation complex; IDA:CAFA.
DR   GO; GO:0016407; F:acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB.
DR   GO; GO:0000993; F:RNA polymerase II complex binding; IDA:UniProtKB.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0016251; F:RNA polymerase II general transcription initiation factor activity; IDA:ARUK-UCL.
DR   GO; GO:0017025; F:TBP-class protein binding; IPI:CAFA.
DR   GO; GO:0046966; F:thyroid hormone receptor binding; IPI:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006352; P:DNA-templated transcription, initiation; IBA:GO_Central.
DR   GO; GO:1904798; P:positive regulation of core promoter binding; IDA:GO_Central.
DR   GO; GO:0006473; P:protein acetylation; IDA:UniProtKB.
DR   GO; GO:1990114; P:RNA polymerase II core complex assembly; IMP:UniProtKB.
DR   GO; GO:0051123; P:RNA polymerase II preinitiation complex assembly; IDA:UniProtKB.
DR   GO; GO:0042795; P:snRNA transcription by RNA polymerase II; TAS:Reactome.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IDA:ARUK-UCL.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0001174; P:transcriptional start site selection at RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:0019083; P:viral transcription; IDA:GO_Central.
DR   CDD; cd00043; CYCLIN; 2.
DR   IDEAL; IID00314; -.
DR   InterPro; IPR013763; Cyclin-like.
DR   InterPro; IPR036915; Cyclin-like_sf.
DR   InterPro; IPR000812; TFIIB.
DR   InterPro; IPR023486; TFIIB_CS.
DR   InterPro; IPR013150; TFIIB_cyclin.
DR   InterPro; IPR013137; Znf_TFIIB.
DR   PANTHER; PTHR11618; PTHR11618; 1.
DR   Pfam; PF08271; TF_Zn_Ribbon; 1.
DR   Pfam; PF00382; TFIIB; 2.
DR   PRINTS; PR00685; TIFACTORIIB.
DR   SMART; SM00385; CYCLIN; 2.
DR   SUPFAM; SSF47954; SSF47954; 2.
DR   PROSITE; PS00782; TFIIB; 2.
DR   PROSITE; PS51134; ZF_TFIIB; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Acyltransferase; Chromosome; DNA-binding;
KW   Host-virus interaction; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Transferase; Zinc; Zinc-finger.
FT   CHAIN           1..316
FT                   /note="Transcription initiation factor IIB"
FT                   /id="PRO_0000119293"
FT   REPEAT          124..200
FT                   /note="1"
FT   REPEAT          218..294
FT                   /note="2"
FT   ZN_FING         11..42
FT                   /note="TFIIB-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00469"
FT   REGION          189..193
FT                   /note="Core promoter DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:10619841"
FT   REGION          244..316
FT                   /note="Necessary for TATA box-bound TBP complex formation"
FT                   /evidence="ECO:0000269|PubMed:8515820,
FT                   ECO:0000269|PubMed:8516311"
FT   REGION          249..252
FT                   /note="Core promoter DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:7675079"
FT   REGION          283..286
FT                   /note="Core promoter DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:10619841,
FT                   ECO:0000269|PubMed:7675079"
FT   METAL           15
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:11045620,
FT                   ECO:0000269|PubMed:14641108, ECO:0007744|PDB:1DL6,
FT                   ECO:0007744|PDB:1RLY"
FT   METAL           18
FT                   /note="Zinc; via tele nitrogen"
FT                   /evidence="ECO:0000269|PubMed:11045620,
FT                   ECO:0000269|PubMed:14641108, ECO:0007744|PDB:1DL6,
FT                   ECO:0007744|PDB:1RLY"
FT   METAL           34
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:11045620,
FT                   ECO:0000269|PubMed:14641108, ECO:0007744|PDB:1DL6,
FT                   ECO:0007744|PDB:1RLY"
FT   METAL           37
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:11045620,
FT                   ECO:0000269|PubMed:14641108, ECO:0007744|PDB:1DL6,
FT                   ECO:0007744|PDB:1RLY"
FT   MOD_RES         70
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         76
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         92
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         238
FT                   /note="N6-acetyllysine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12931194"
FT   VARIANT         19
FT                   /note="P -> S (in dbSNP:rs1804499)"
FT                   /id="VAR_011977"
FT   VARIANT         132
FT                   /note="R -> Q (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs144944840)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035722"
FT   MUTAGEN         37
FT                   /note="C->S: Does not inhibit interaction with TBP.
FT                   Inhibits the recruitment of RNA polymerase II into the
FT                   initiation complex."
FT                   /evidence="ECO:0000269|PubMed:8516312"
FT   MUTAGEN         51..56
FT                   /note="EWRTFS->AWRTFA: Partial loss of HIV-1 Vpr binding."
FT                   /evidence="ECO:0000269|PubMed:10359081"
FT   MUTAGEN         51
FT                   /note="E->R,A,D: Defects in transcription start site
FT                   selection. Supports a level of transcription equivalent to
FT                   wild-type."
FT                   /evidence="ECO:0000269|PubMed:10318856"
FT   MUTAGEN         52
FT                   /note="W->A: Partial loss of HIV-1 Vpr binding."
FT                   /evidence="ECO:0000269|PubMed:10359081"
FT   MUTAGEN         53..54
FT                   /note="RT->AA: Partial loss of HIV-1 Vpr binding."
FT                   /evidence="ECO:0000269|PubMed:10359081"
FT   MUTAGEN         55
FT                   /note="F->A: Partial loss of HIV-1 Vpr binding."
FT                   /evidence="ECO:0000269|PubMed:10359081"
FT   MUTAGEN         66
FT                   /note="R->A,E,K: Defects in transcription start site
FT                   selection. Supports a level of transcription equivalent to
FT                   wild-type."
FT                   /evidence="ECO:0000269|PubMed:10318856"
FT   MUTAGEN         153
FT                   /note="G->Q: Decreases BREd-dependent pre-initiation
FT                   complex formation."
FT                   /evidence="ECO:0000269|PubMed:16230532"
FT   MUTAGEN         185
FT                   /note="R->E: Reduces interaction with SSU72; when
FT                   associated with E-193 or E-200. Inhibits interaction with
FT                   VP16; when associated with E-193. Inhibits RNA pol II
FT                   transcription activation induced by VP16 but does not
FT                   affect basal transcription; when associated with E-193."
FT                   /evidence="ECO:0000269|PubMed:29158257,
FT                   ECO:0000269|PubMed:8515819"
FT   MUTAGEN         185
FT                   /note="R->L: Reduces interaction with VP16; when associated
FT                   with L-189."
FT                   /evidence="ECO:0000269|PubMed:8515819"
FT   MUTAGEN         189
FT                   /note="K->E: Inhibits interaction with SSU72; when
FT                   associated with E-193. Reduces interaction with SSU72; when
FT                   associated with E-200. Inhibits interaction with VP16; when
FT                   associated with E-200. Inhibits RNA pol II transcription
FT                   activation induced by VP16 but does not affect basal
FT                   transcription; when associated with E-200."
FT                   /evidence="ECO:0000269|PubMed:29158257,
FT                   ECO:0000269|PubMed:8515819"
FT   MUTAGEN         189
FT                   /note="K->L: Reduces interaction with VP16; when associated
FT                   with L-185."
FT                   /evidence="ECO:0000269|PubMed:8515819"
FT   MUTAGEN         193
FT                   /note="R->E: Inhibits interaction with SSU72; when
FT                   associated with E-185 or E-189. Inhibits interaction with
FT                   VP16; when associated with E-185. Inhibits RNA pol II
FT                   transcription activation induced by VP16 but does not
FT                   affect basal transcription; when associated with E-185."
FT                   /evidence="ECO:0000269|PubMed:29158257,
FT                   ECO:0000269|PubMed:8515819"
FT   MUTAGEN         196
FT                   /note="K->L: Reduces interaction with VP16; when associated
FT                   with L-200."
FT                   /evidence="ECO:0000269|PubMed:8515819"
FT   MUTAGEN         200..208
FT                   /note="KALETSVDL->GSGS: Reduces the formation of the TATA
FT                   box-bound TBP ternary complex."
FT                   /evidence="ECO:0000269|PubMed:29158257"
FT   MUTAGEN         200
FT                   /note="K->E: Reduces interaction with SSU72; when
FT                   associated with E-185 or E-189. Inhibits interaction with
FT                   VP16; when associated with E-189. Inhibits RNA pol II
FT                   transcription activation induced by VP16 but does not
FT                   affect basal transcription; when associated with E-189."
FT                   /evidence="ECO:0000269|PubMed:29158257,
FT                   ECO:0000269|PubMed:8515819"
FT   MUTAGEN         200
FT                   /note="K->KGSGS: Reduces the formation of the TATA box-
FT                   bound TBP ternary complex."
FT                   /evidence="ECO:0000269|PubMed:29158257"
FT   MUTAGEN         200
FT                   /note="K->L: Reduces interaction with VP16; when associated
FT                   with L-196."
FT                   /evidence="ECO:0000269|PubMed:8515819"
FT   MUTAGEN         208
FT                   /note="L->LGSGS: Does not inhibit the formation of the TATA
FT                   box-bound TBP ternary complex."
FT                   /evidence="ECO:0000269|PubMed:29158257"
FT   MUTAGEN         238
FT                   /note="K->A: Abolishes autoacetylation, represses
FT                   transcription activity, does not inhibit its association
FT                   with chromatin to promoter-specific regions and decreases
FT                   the association of GTF2F1 with chromatin to promoter-
FT                   specific regions."
FT                   /evidence="ECO:0000269|PubMed:12931194"
FT   MUTAGEN         247
FT                   /note="G->V: Inhibits interaction with TBP."
FT                   /evidence="ECO:0000269|PubMed:8516312"
FT   MUTAGEN         283
FT                   /note="V->A: Reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:9420329"
FT   MUTAGEN         286
FT                   /note="R->A: Reduces DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:9420329"
FT   MUTAGEN         286
FT                   /note="R->E: Inhibits interaction with RNA polymerase II;
FT                   when associated with E-290 and E-295."
FT                   /evidence="ECO:0000269|PubMed:8504927"
FT   MUTAGEN         290
FT                   /note="R->E: Inhibits interaction with RNA polymerase II;
FT                   when associated with E-286 and E-295."
FT                   /evidence="ECO:0000269|PubMed:8504927"
FT   MUTAGEN         295
FT                   /note="R->E: Inhibits interaction with RNA polymerase II;
FT                   when associated with E-286 and E-290."
FT                   /evidence="ECO:0000269|PubMed:8504927"
FT   STRAND          4..6
FT                   /evidence="ECO:0007744|PDB:1RLY"
FT   STRAND          18..21
FT                   /evidence="ECO:0007744|PDB:1DL6"
FT   STRAND          24..26
FT                   /evidence="ECO:0007744|PDB:1RO4"
FT   STRAND          27..29
FT                   /evidence="ECO:0007744|PDB:1DL6"
FT   TURN            35..37
FT                   /evidence="ECO:0007744|PDB:1DL6"
FT   HELIX           111..113
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           114..127
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           132..148
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           149..151
FT                   /evidence="ECO:0007744|PDB:5WH1"
FT   STRAND          152..154
FT                   /evidence="ECO:0007744|PDB:5WH1"
FT   HELIX           156..170
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           177..182
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   STRAND          184..186
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           188..201
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           212..221
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           226..241
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           250..263
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   STRAND          265..267
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           271..278
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           282..292
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           293..295
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           296..299
FT                   /evidence="ECO:0007744|PDB:1C9B"
FT   HELIX           310..312
FT                   /evidence="ECO:0007744|PDB:1VOL"
SQ   SEQUENCE   316 AA;  34833 MW;  9CC7E102526C2722 CRC64;
     MASTSRLDAL PRVTCPNHPD AILVEDYRAG DMICPECGLV VGDRVIDVGS EWRTFSNDKA
     TKDPSRVGDS QNPLLSDGDL STMIGKGTGA ASFDEFGNSK YQNRRTMSSS DRAMMNAFKE
     ITTMADRINL PRNIVDRTNN LFKQVYEQKS LKGRANDAIA SACLYIACRQ EGVPRTFKEI
     CAVSRISKKE IGRCFKLILK ALETSVDLIT TGDFMSRFCS NLCLPKQVQM AATHIARKAV
     ELDLVPGRSP ISVAAAAIYM ASQASAEKRT QKEIGDIAGV ADVTIRQSYR LIYPRAPDLF
     PTDFKFDTPV DKLPQL
//
